–
Статьи в журналах
-
- 2022 Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
- Gilberto de Castro Jr, Kudaba Iveta, Wu Yi-Long, Lopes Gilberto, Kowalski Dariusz M., Turna Hande Z., Caglevic Christian, Li Zhang, Karaszewska Boguslawa, Laktionov Konstantin K., Srimuninnimit Vichien, Bondarenko Igor, Kubota Kaoru, Mukherjee Rinee, Lin Jianxin, Souza Fabricio, Mok Tony S.K., Cho Byoung Chul
- в журнале Journal of Clinical Oncology, издательство American Society of Clinical Oncology (United States), с. 1-7